Gland Pharma (NSE:GLAND) Non Operating Income: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
80 GF Score
Price ₹2,820.00
GF Value ₹2,242.92
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Non Operating Income?

Gland Pharma NSE:GLAND -0.75% 80 Non Operating Income is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 80/100 and a GF Value™ of ₹2,242.92 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Gland Pharma's Non Operating Income for the three months ended in Jun. 2026 was ₹0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Gland Pharma Non Operating Income Related Terms

Gland Pharma Non Operating Income Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Non Operating Income Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gland Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GLAND
80GF Score
Gland Pharma Ltd NSE:GLAND
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of ₹0 Mil mean?
Gland Pharma (NSE:GLAND) has a Non Operating Income of ₹0 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Non Operating Income too high?
Gland Pharma's current Non Operating Income is ₹0 Mil. Overall, Gland Pharma has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Non Operating Income compare to ZTS?
Gland Pharma's Non Operating Income of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Gland Pharma and its competitors. Gland Pharma's current Non Operating Income is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,242.92, compared to a current price of ₹2,820.00 — trading 25.7% above its estimated fair value. The current Non Operating Income is ₹0 Mil. Gland Pharma's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Non Operating Income is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,820.00 is trading 25.7% above its estimated GF Value™ of ₹2,242.92. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Non Operating Income: ₹0 Mil
  • GF Value™: ₹2,242.92 vs. price of ₹2,820.00 (25.7% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
80GF Score

Get the complete analysis for NSE:GLAND

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,820.00
Price
₹2,242.92
GF Value